We suspect that the complete clinical spectrum of BET1 variants will be more fully characterized with the identification of additional affected individuals, and similarly to GOSR2, the phenotype may be a spectrum, ranging from a predominant epilepsy syndrome at one end of the spectrum to an α‐DG‐related CMD with refractory epilepsy at the other, more severe end of the spectrum. This evidence concerns the gene BET1 and epilepsy syndrome.